Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials

An announcement from Tvardi Therapeutics ( (TVRD) ) is now available.

Tvardi Therapeutics announced significant progress in its clinical trials, particularly with its STAT3 inhibitor, TTI-101, which has shown promising results in reducing inflammation, fibrosis, and tumor growth in hepatocellular carcinoma (HCC) models. The company is also conducting ongoing Phase 1 and Phase 2 trials, with anticipated data releases in the first half of 2026, potentially impacting the treatment landscape for fibrosis-driven diseases and HCC.

The most recent analyst rating on (TVRD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.

Spark’s Take on TVRD Stock

According to Spark, TipRanks’ AI Analyst, TVRD is a Underperform.

Cara Therapeutics receives a low overall stock score due to significant financial challenges, including declining revenues and negative profitability. Technical analysis indicates a bearish trend with weak market momentum, and valuation metrics highlight ongoing losses. These factors collectively suggest a high-risk profile for potential investors.

To see Spark’s full report on TVRD stock, click here.

More about Tvardi Therapeutics

Tvardi Therapeutics operates in the biotechnology industry, focusing on developing therapies targeting the STAT3 pathway, which is implicated in fibrosis-driven diseases and certain cancers. The company is advancing its product candidates through various stages of clinical trials, aiming to provide disease-modifying treatments.

Average Trading Volume: 283,267

Technical Sentiment Signal: Strong Sell

Current Market Cap: $37.81M

For detailed information about TVRD stock, go to TipRanks’ Stock Analysis page.